BioSpace News Archive

Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new data demonstrating the potential of CPI-818, the Company’s ITK inhibitor, to reduce the need for chronic human immunodeficiency virus (HIV) therapy.

First Wave BioPharma, Inc. announced that an abstract entitled, “Results from an Open-Label, Phase 2 Study with Escalating Doses of Adrulipase Alfa on top of a Stable Dose of Porcine Pancreatic Enzymes in CF Patients Not Fully Compensated with PPE as Sole Therapy,” has been accepted for a presentation at the 2023 Digestive Disease Week Conference.

Assertio Holdings, Inc. announced preliminary, unaudited financial results for its fourth quarter and full year 2022, ended December 31, 2022, including its highest quarter of net product sales in the past five years.

Algernon Pharmaceuticals Inc., a clinical stage pharmaceutical development company, is pleased to announce that its subsidiary Algernon NeuroScience has added a new clinical research program for the treatment of Traumatic Brain Injury with AP-188.

BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a corporate update.

Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the submission of its supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) to request approval of XHANCE as a treatment for chronic rhinosinusitis.

uniQure N.V. (NASDAQ: QURE) announced that its partner, global biotechnology leader CSL (ASX: CSL), has received conditional marketing authorization (CMA) from the European Commission for HEMGENIX® (etranacogene dezaparvovec), the first and only one-time gene therapy for the treatment of severe and moderately severe hemophilia B.

Evoke Pharma, Inc. today announced that its abstract entitled “Reducing Real-World Healthcare Resource Utilization For Patients With Diabetic Gastroparesis (DGP) Treated with Metoclopramide Nasal Spray Versus Oral Metoclopramide” has been selected for the plenary lecture presentation at the upcoming Digestive Disease Week (DDW) 2023.

3H Medi Solution Inc., a leading Japanese clinical trial company, today announced its selection of THREAD to expand decentralized research capabilities and improve access to clinical research for patients in Japan.

Avanos Medical, Inc. (NYSE: AVNS) today reported fourth quarter and full-year 2022 results.